Jazz Pharmaceuticals plc and Amneal Pharmaceuticals, Inc.: A Detailed Gross Profit Analysis

Jazz vs. Amneal: A Decade of Gross Profit Growth

__timestampAmneal Pharmaceuticals, Inc.Jazz Pharmaceuticals plc
Wednesday, January 1, 20144496340001055457000
Thursday, January 1, 20154992260001222277000
Friday, January 1, 20165974550001382587000
Sunday, January 1, 20175261780001508505000
Monday, January 1, 20187164030001769378000
Tuesday, January 1, 20193529970002033831000
Wednesday, January 1, 20206283930002214650000
Friday, January 1, 20217689730002653478000
Saturday, January 1, 20227847080003118857000
Sunday, January 1, 20238205650003398627000
Loading chart...

Unleashing insights

A Tale of Two Pharmaceuticals: Jazz vs. Amneal

In the competitive landscape of pharmaceuticals, Jazz Pharmaceuticals plc and Amneal Pharmaceuticals, Inc. have shown distinct trajectories in their gross profit margins over the past decade. From 2014 to 2023, Jazz Pharmaceuticals has consistently outperformed Amneal, with its gross profit growing by over 220%, reaching a peak in 2023. In contrast, Amneal's growth has been more modest, with a 82% increase over the same period.

Key Insights

  • Jazz Pharmaceuticals: Starting at approximately $1.1 billion in 2014, Jazz's gross profit surged to nearly $3.4 billion by 2023, reflecting its robust market strategies and product innovations.
  • Amneal Pharmaceuticals: Despite a slower growth rate, Amneal's gross profit rose from around $450 million in 2014 to over $820 million in 2023, indicating steady progress.

This analysis highlights the dynamic nature of the pharmaceutical industry and the varying strategies companies employ to achieve financial success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025